Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BELIEVE III: Cenderitide for LV function preservation post-STEMI
NCT02071602Phase 1Completed
- Sponsor
- Mayo Clinic
- Start
- Oct 2013
- Primary completion
- May 2018
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of cenderitide in acute ST-segment elevation myocardial infarction (STEMI) (3 arms), sponsored by Mayo Clinic. Primary endpoint: Number of subjects with symptomatic hypotension at 30 days. Started Oct 2013; status: completed.
02
Drugs
cenderitide
03
Conditions
acute ST-segment elevation myocardial infarction (STEMI)
Beyond the preview
Go deeper on NCT02071602.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02071602.